Figure 2

CDH16 immunostaining in cancer. The panels show a predominantly membranous CDH16 immunostaining of variable intensity in samples from a chromophobe (A) and a clear cell renal cell carcinoma (B), a clear cell carcinoma of the ovary (C), an adenocarcinoma of the cervix uteri (D), a nephrogenic adenoma (E), and a follicular adenoma of the thyroid (F). Samples from CDH16 negative papillary carcinomas of the thyroid are depicted in (G) and—adjacent to CDH16 positive normal thyroid follicles—in (H).